Encore Medical Inc. is expected to list on the NYSE on 2026-10-01, but the price range has not been disclosed yet. The setup is straightforward: a structural heart device company with real revenue growth, but also ongoing losses and a hard regulatory path in the U.S.
Encore Medical Inc. is expected to list on the NYSE on 2026-10-01, but the price range has not been disclosed yet. The setup is straightforward: a structural heart device company with real revenue growth, but also ongoing losses and a hard regulatory path in the U.S.
Quick Facts
Expected listing date: October 1, 2026
Exchange: NYSE
Proposed symbol: EMI
Status: Expected
Company Overview
Encore Medical Inc. is a structural heart device company focused on transcatheter closure of certain cardiac defects, especially patent foramen ovale, or PFO, closure. The company develops and markets septal occlusion products and related delivery systems, and it recognizes revenue when devices ship. In 2024, it generated $2,134,528 of net sales, up from $1,434,424 in 2023, and it says sales are already coming from outside the United States while it works toward a U.S. launch.
The company was incorporated in Minnesota on September 26, 2017, and is headquartered in Eagan, Minnesota. Its filing frames the opportunity around a large but regulated market: PFO occurs in about 25% of adults, about 50% of cryptogenic stroke patients are later found to have a PFO, and the company estimates about 250,000 cases per year worldwide require immediate closure due to cryptogenic stroke. It also cites a potential multi-billion-dollar migraine-related opportunity and says there are 10 million+ potential U.S. patients. The competitive backdrop is concentrated, with Abbott and W.L. Gore currently the only companies with FDA approval to sell PFO devices in the U.S.
Why They're Going Public
Encore says the main purpose of the offering is to raise capital for clinical trials, especially for stroke and migraine indications, along with working capital and general corporate purposes. Management will have broad discretion over how the proceeds are used.
Going public also gives the company a larger balance-sheet platform as it tries to move from an international commercial base into the U.S. market. That matters because the filing says the U.S. average retail price is about $11,000 per device, versus $2,000 to $4,000 per device outside the United States, so a successful U.S. approval path could materially change the economics of the business.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Encore is growing from a small base, but the top line is moving in the right direction. Net sales rose 48.8% year over year to $2,134,528 in 2024 from $1,434,424 in 2023, an increase of $700,104. Gross profit increased to $773,451 in 2024 from $522,346 in 2023, while gross margin stayed roughly flat at 36.2% versus 36.4%.
The more encouraging trend is in the first half of 2025, where gross profit was $408,008 and gross margin improved to 40.4% from 25.1% in the prior-year period. Even so, the company remains loss-making: net loss widened to $(1,845,951) in 2024 from $(1,386,857) in 2023. The filing excerpt reviewed did not clearly surface a cash balance, but the company says it needs additional capital and may be unable to continue as a going concern without it.
Risk Factors
The biggest risk is regulatory execution. Encore’s U.S. PFO device requires FDA approval, and the filing says the company must complete its clinical trial and submit a PMA for final approval. If the trial is delayed, fails, or does not support approval, the U.S. growth story gets pushed out. The company also says clinical results may not match prior experience, which is a real issue for a device business trying to move from development into commercialization.
There are also classic medtech risks: the industry is highly competitive and heavily regulated, reimbursement matters, product liability exposure is real, and the company will need more capital to commercialize its products. The filing also flags intellectual property enforcement risk, export/import and tariff exposure, and EU regulatory reforms. On top of that, the company and its directors, officers, and holders of 2% or more of common stock agreed to a 180-day lockup, so shareholders should watch for dilution pressure once that period expires.
Comparable Public Companies
The closest public comps are Abbott (ABT), Boston Scientific (BSX), Medtronic (MDT), Edwards Lifesciences (EW), and Integer Holdings (ITGR). For Encore, Abbott and Boston Scientific are the most relevant strategic comparables because they operate in structural heart and broader medtech, while Medtronic and Edwards help frame the premium valuation profile that can exist in device names with durable growth and regulatory moats. Integer is a useful reminder that medtech supply-chain and component businesses can trade differently from branded device makers.
On relative scale, Encore is tiny: 2024 net sales were just $2.1 million, versus multibillion-dollar revenue bases for the public peers. That means the IPO is more of an early-stage regulatory and commercialization story than a mature operating company comparison. I did not pull live market multiples in this pass, so I can’t responsibly quote current valuation ranges; broadly, the sector has been mixed rather than uniformly hot, with higher-quality medtech names typically holding up better than pre-profit development stories. For readers, the key question is whether the market is willing to pay up for a small device company with a clear clinical catalyst but no U.S. approval yet.
Verdict
The main thing to watch as Encore prices is whether investors are willing to underwrite the FDA path rather than just the current revenue base. This is a pre-pricing IPO with no disclosed price range, so the setup favors a watchlist approach: the bull case is a differentiated structural heart platform with 48.8% 2024 revenue growth and improving gross margin, while the bear case is that the company is still loss-making, needs more capital, and must clear a demanding regulatory process before the U.S. market opens up.
This IPO matters now because it sits at the intersection of two narratives that can still attract capital: medtech innovation and a large unmet-need market in stroke and migraine. But the timing angle cuts both ways. The company is coming public before the key U.S. approval milestone, which makes the story more speculative than a late-stage commercial launch. Shareholders should watch the pricing, the size of the float, and any update on clinical progress, because those will tell you whether the market sees Encore as an emerging platform or a long-dated regulatory bet.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
